Intraoperative AwarenessPhase 4NCT07513935
Comparison of Combined Dexmedetomidine and Ketamine (Ketodex) Versus Dexmedetomidine Alone in Awake Mapping for Deep Brain Stimulation: A Randomized Controlled Trial
A Phase 4 study testing Ketodex and Dexmedetomidine in people with Intraoperative Awareness, run by Ain Shams University at 1 site in Egypt.
Trial summary
Adult patients undergoing awake Deep Brain Stimulation (DBS) surgery for movement disorders (e.g., Parkinson's Disease, Essential Tremor). Study groups After approved by Local Institutional Ethics Committee and obtaining written informed consent ....pt Divided in two groups Group I (KD1): (n = 12) ....patients who… Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Intraoperative Awareness
- What is being tested?
- Ketodex and Dexmedetomidine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteEgypt
- Study dates
- 3 Mar 2026to 30 Sep 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18-75 years.
- American Society of Anesthesiologists (ASA) physical status I, II, or III.
- Ability to give informed consent and cooperate with the procedure (e.g., follow commands, perform intraoperative tasks).
Who cannot join
- Contraindications to the study drugs (dexmedetomidine or ketamine).
- Severe cardiac, respiratory, or hepatic disease.
- Pre-existing psychological/psychiatric disorders that may interfere with intraoperative assessment (e.g., severe dementia, psychosis).
- Allergy to local anesthetics.
- Emergency surgery or previous DB
- Electrocardiogram (ECG) showing heart block of any degree
Show all 9Show fewer
- heart failure,
- liver cirrhosis, thrombocytopenia and coagulopathies,
- severe bradycardia,
Trial locations and contacts
1 site in 1 country.
About this study
Adult patients undergoing awake Deep Brain Stimulation (DBS) surgery for movement disorders (e.g., Parkinson's Disease, Essential Tremor).
Study groups After approved by Local Institutional Ethics Committee and obtaining written informed consent ....pt Divided in two groups Group I (KD1): (n = 12) ....patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of dexmedetomidine (Precedex, 100 μg/ml, Hospira, USA) in a rate of 0.1-0.5 ug/kg/hour and ketamine infusion 0.1mg / kg/hr until the .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedo-analgesic when required and recorded.
Read more
Group II (D2): (n =12 ) ......patients who received (I.V.) dexmedetomidine in a dose of 0.5 μg/ kg diluted in 5-ml. normal saline followed by continuous infusion of dexmedetomidine in a rate of 0.1-0.5 μg/kg/hour (Precedex, 100μg/ml, Hospira, USA) until Sedation Scorethe .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted.... and BIS range of 50-70 will be adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedoanalgesic when required and recorded.
Anesthetic Protocol (Standardized) Monitoring Up on arrival to operating theatre, routine monitoring devices will be placed and baseline ECG, mean arterial pressure (MAP) and oxygen saturation (SpO2 ) will be recorded. Using Datexohmeda (GE Healthcare Co., USA) and continued till shifting out to the recovery room. The baseline values of H.R., mean arterial pressure (MAP), SPO2, and respiratory rate (RR) will be recorded.
- Bispectral index (BIS) monitoring throughout whole procedure
- Root Mean Square (RMS): The Root Mean Square (RMS) value of the recorded signal, often measured in volts, is a key parameter. A higher RMS value is often associated with entering the target nucleus, which is rich in neuronal activity.
- Normalized RMS (NRMS): To account for variations, the RMS is often normalized (NRMS) by dividing the RMS of a segment by the average RMS of a baseline segment (e.g., the first five stable sessions). A common indicator for good signal amplitude within the STN, for example, is an average NRMS greater than 2.0.
Following 8 hours period of fasting before the procedure, peripheral I.V. line established with a 20G cannula and lactated Ringer's will be infused At a rate of 6-8ml/kg/hour and oxygen 3 l/min will be administered through a nasal cannula. During the procedure, monitoring of HR, MAP, SPO2,and RR will be recorded every 2 min for the first 10 min, thereafter every 5 min until the end of the procedure.
Premedication: A standardized dose of midazolam (e.g., 0.02 mg/kg IV) Ondansterone 4 mg iv as antiemetic
Drug Administration:
Dexmedetomidine: A loading dose (e.g., 0.5 mcg/kg over 10-15 minutes) followed by a maintenance infusion ( 0.1 to 0.5 u g/kg/hour).
this dose not affecting MER Ketamine (in Group DK): A low-dose continuous infusion (0.05mg/kg/hr to 0.25 mg/kg/hour) this dose not affecting MER started concurrently with dexmedetomidine. SO the investigators will decrease the loading dose of dexmedotomidine to 0.25 mcg /kg in group Accounting for synergitic effect Local Anesthesia: Standardized scalp block and local infiltration (e.g., lidocaine with epinephrine).
Rescue Analgesia/Sedation: Fentanyl (e.g., 25-50 \mu g IV bolus) will be used as rescue analgesia for both groups, as needed.
If agitation is refractory, an unblinded investigator member may administer a rescue sedative (e.g., propofol), which must be recorded .
Titration: Infusions will be titrated based on the patient's sedation level, using a validated scale Following the bolus doses, sedation score was assessed by anesthesiologist unaware of regime used by the Richmond Agitation-Sedation Scale (RASS) Score Term Description
- 4 Combative Overtly combative or violent; immediate danger to staff.
- 3 Very Agitated Pulls on or removes tube(s) or catheter(s) or has aggressive behavior toward staff.
- 2 Agitated Frequent non-purposeful movement or patient-ventilator dyssynchrony.
- 1 Restless Anxious or apprehensive but movements not aggressive or vigorous. 0 Alert and Calm Spontaneously pays attention to caregiver.
- 1 Drowsy Not fully alert, but has sustained (more than 10 seconds) awakening, with eye contact, to voice.
- 2 Light Sedation Briefly (less than 10 seconds) awakens with eye contact to voice.
- 3 Moderate Sedation Any movement (but no eye contact) to voice.
- 4 Deep Sedation No response to voice, but any movement to physical stimulation.
- 5 Unarousable No response to voice or physical stimulation.
- Conditions
- Intraoperative Awareness
- Being tested
- Ketodex, Dexmedetomidine
- Medical subject headings
- Intraoperative Awareness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KetodexDrug
Group I (KD1): (n = 12) ....patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of dexmedetomidine (Precedex, 100 μg/ml, Hospira, USA) in a rate of 0.1-0.5 ug/kg/hour and ketamine infusion 0.1mg / kg/hr until the .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedo-analgesic when required and recorded.
DexmedetomidineDrug
Group II (D2): (n =12 ) ......patients who received (I.V.) dexmedetomidine in a dose of 0.5 μg/ kg diluted in 5-ml. normal saline followed by continuous infusion of dexmedetomidine in a rate of 0.1-0.5 μg/kg/hour (Precedex, 100μg/ml, Hospira, USA) until Sedation Scorethe .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted.... and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg was administered intravenously as rescue sedoanalgesic when required and recorded.
| Study group | Role | What they receive |
|---|---|---|
| Group I (KD1 | Active comparator | Not described Receives: Drug: Ketodex |
| Group II (D2): | Active comparator | Not described Receives: Drug: Dexmedetomidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
• the NRMS Assessment
Measured: perioperative period
Secondary outcomes (4)
Total Rescue Analgesia
Total dose of fentanyl (or other opioids) required during the surgery.
Measured: perioperative period
Time to Awakeness/Recovery
Time from the end of surgery to achieve a specific RASS score (e.g., 0 or +1) or a modified Aldrete score suitable for PACU transfer.
Measured: perioperative period
Neurocognitive Assessment
Measured: preoperative 6 hours and 24 hours postoperatively
incidence of hypotension and bradycardia
Measured: perioperative period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2026
- Study start3 Mar 2026
- Primary completion3 Sep 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intraoperative AwarenessStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ismail Mohammed, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07513935
- Sponsor's protocol ID
- FMASU R51/2026
- Status last verified
- Apr 2026
- First submitted
- 13 Mar 2026
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Combined Dexmedetomidine and Ketamine (Ketodex) Versus Dexmedetomidine Alone in Awake Mapping for Deep Brain Stimulation: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07513935
- Acronym / sponsor ID
- FMASU R51/2026
- Conditions
- Intraoperative Awareness
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 3 Mar 2026 (actual)
- Primary completion
- 3 Sep 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 7 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adult patients undergoing awake Deep Brain Stimulation (DBS) surgery for movement disorders (e.g., Parkinson's Disease, Essential Tremor).
Study groups After approved by Local Institutional Ethics Committee and obtaining written informed consent ....pt Divided in two groups Group I (KD1): (n = 12) ....patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of dexmedetomidine (Precedex, 100 μg/ml, Hospira, USA) in a rate of 0.1-0.5 ug/kg/hour and ketamine infusion 0.1mg / kg/hr until the .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedo-analgesic when required and recorded.
Group II (D2): (n =12 ) ......patients who received (I.V.) dexmedetomidine in a dose of 0.5 μg/ kg diluted in 5-ml. normal saline followed by continuous infusion of dexmedetomidine in a rate of 0.1-0.5 μg/kg/hour (Precedex, 100μg/ml, Hospira, USA) until Sedation Scorethe .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted.... and BIS range of 50-70 will be adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedoanalgesic when required and recorded.
Anesthetic Protocol (Standardized) Monitoring Up on arrival to operating theatre, routine monitoring devices will be placed and baseline ECG, mean arterial pressure (MAP) and oxygen saturation (SpO2 ) will be recorded. Using Datexohmeda (GE Healthcare Co., USA) and continued till shifting out to the recovery room. The baseline values of H.R., mean arterial pressure (MAP), SPO2, and respiratory rate (RR) will be recorded.
- Bispectral index (BIS) monitoring throughout whole procedure
- Root Mean Square (RMS): The Root Mean Square (RMS) value of the recorded signal, often measured in volts, is a key parameter. A higher RMS value is often associated with entering the target nucleus, which is rich in neuronal activity.
- Normalized RMS (NRMS): To account for variations, the RMS is often normalized (NRMS) by dividing the RMS of a segment by the average RMS of a baseline segment (e.g., the first five stable sessions). A common indicator for good signal amplitude within the STN, for example, is an average NRMS greater than 2.0.
Following 8 hours period of fasting before the procedure, peripheral I.V. line established with a 20G cannula and lactated Ringer's will be infused At a rate of 6-8ml/kg/hour and oxygen 3 l/min will be administered through a nasal cannula. During the procedure, monitoring of HR, MAP, SPO2,and RR will be recorded every 2 min for the first 10 min, thereafter every 5 min until the end of the procedure.
Premedication: A standardized dose of midazolam (e.g., 0.02 mg/kg IV) Ondansterone 4 mg iv as antiemetic
Drug Administration:
Dexmedetomidine: A loading dose (e.g., 0.5 mcg/kg over 10-15 minutes) followed by a maintenance infusion ( 0.1 to 0.5 u g/kg/hour).
this dose not affecting MER Ketamine (in Group DK): A low-dose continuous infusion (0.05mg/kg/hr to 0.25 mg/kg/hour) this dose not affecting MER started concurrently with dexmedetomidine. SO the investigators will decrease the loading dose of dexmedotomidine to 0.25 mcg /kg in group Accounting for synergitic effect Local Anesthesia: Standardized scalp block and local infiltration (e.g., lidocaine with epinephrine).
Rescue Analgesia/Sedation: Fentanyl (e.g., 25-50 \mu g IV bolus) will be used as rescue analgesia for both groups, as needed.
If agitation is refractory, an unblinded investigator member may administer a rescue sedative (e.g., propofol), which must be recorded .
Titration: Infusions will be titrated based on the patient's sedation level, using a validated scale Following the bolus doses, sedation score was assessed by anesthesiologist unaware of regime used by the Richmond Agitation-Sedation Scale (RASS) Score Term Description
- 4 Combative Overtly combative or violent; immediate danger to staff.
- 3 Very Agitated Pulls on or removes tube(s) or catheter(s) or has aggressive behavior toward staff.
- 2 Agitated Frequent non-purposeful movement or patient-ventilator dyssynchrony.
- 1 Restless Anxious or apprehensive but movements not aggressive or vigorous. 0 Alert and Calm Spontaneously pays attention to caregiver.
- 1 Drowsy Not fully alert, but has sustained (more than 10 seconds) awakening, with eye contact, to voice.
- 2 Light Sedation Briefly (less than 10 seconds) awakens with eye contact to voice.
- 3 Moderate Sedation Any movement (but no eye contact) to voice.
- 4 Deep Sedation No response to voice, but any movement to physical stimulation.
- 5 Unarousable No response to voice or physical stimulation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I (KD1 | Active comparator | Drug: Ketodex |
| Group II (D2): | Active comparator | Drug: Dexmedetomidine |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18-75 years.
Key exclusion criteria (9 listed)
- Contraindications to the study drugs (dexmedetomidine or ketamine).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KetodexGroup I (KD1): (n = 12) ....patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of dexmedetomidine (Precedex, 100 μg/ml, Hospira, USA) in a rate of 0.1-0.5 ug/kg/hour and ketamine infusion 0.1mg / kg/hr until the .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedo-analgesic when required and recorded. | Drug | Group I (KD1 |
| DexmedetomidineGroup II (D2): (n =12 ) ......patients who received (I.V.) dexmedetomidine in a dose of 0.5 μg/ kg diluted in 5-ml. normal saline followed by continuous infusion of dexmedetomidine in a rate of 0.1-0.5 μg/kg/hour (Precedex, 100μg/ml, Hospira, USA) until Sedation Scorethe .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted.... and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg was administered intravenously as rescue sedoanalgesic when required and recorded. | Drug | Group II (D2): |
Primary outcome
• the NRMS Assessment
Time frame: perioperative period
4 secondary outcomes
Total Rescue Analgesia
Time frame: perioperative period
Time to Awakeness/Recovery
Time frame: perioperative period
Neurocognitive Assessment
Time frame: preoperative 6 hours and 24 hours postoperatively
incidence of hypotension and bradycardia
Time frame: perioperative period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Intraoperative Awareness
Not yet recruitingObservational study
Evaluation of Consciousness Depth (qCON) and Analgesia Depth (qNOX) Indices in General Anesthesia
Cesarean Section (MeSH: D002585), Anesthesia
RecruitingObservational study
Evaluation of Intraoperative Awareness and Its Correlation With Processed EEG Biomarkers During Laparoscopic Surgery
Intraoperative Awareness, Intraoperative Responsiveness During General Anesthesia
Recruiting
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
Surgery-Complications, Anesthesia Complication
RecruitingObservational study
Fear and Anxiety in Anesthesia-Naïve Patients Pre-operatively vs Post-operatively
Anxiety, Anesthesia Awareness
Not yet recruitingObservational study
Deep Learning Framework for Continuous Depth of Anesthesia Forecasting
BIS, BIS-EEG
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ketodex and Dexmedetomidine in people with Intraoperative Awareness, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
• the NRMS Assessment (time frame: perioperative period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.